Two nutrition-tech businesses are combining across continents. One is Healthify, the Indian wellness app whose AI coaches millions of users. The other is Berry Street, an American clinical network focused on metabolic care. Together they aim to sell AI metabolic care that US health insurers will cover.
The two founders will run the combined business. Vashisht and Kotlove share the CEO title. Berry Street keeps its brand for US customers. Healthify’s name lives on in India and other markets.
The union arrives during a surge of interest in GLP-1 drugs and the programs that support them. Company data shows about a third of Americans now ask AI for health guidance, up sharply in a year. The founders’ wager: consumers will pay for clinical backing that generic chatbots lack.
Healthify’s models grew out of hundreds of millions of dietitian-patient conversations. The company serves more than 45 million people across roughly 20 cultures, and its GLP-1 support work with Novo Nordisk is the fastest-growing line. Berry Street has cared for more than 200,000 patients across the country. The company prescribes GLP-1s when clinically appropriate. It also joined the first CMS ACCESS cohort. Amazon and Walmart help distribute its services.
The pitch to insurers and patients is simple: metabolic care powered by AI, overseen by clinicians, and covered by insurance so out-of-pocket costs stay near zero. That, the founders argue, is what general-purpose AI cannot yet deliver.
